Michael Romig, DO
Cardiovascular Disease · Wilmington, NCNPI 1982917233
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 37.5% of the total. 2025 is the largest year on record at $4,647, 5.1 times the $908 reported in 2019.
Across 357 payments — averaging $44.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6K
- Medtronic$3K
- Abbott$1K
- Novartis$1K
- Abiomed$630
- E.r. Squibb & Sons, L.L.C.$541
- plus $3K from 23 others
Across 2 payments — averaging $8133.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$16K
What the payments were for
- Speaking & faculty fees$4,75030%
- Travel & lodging$2,13813%
- Food & beverage$8,99956%
- Education$660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 71 | $5,982 |
| Medtronic(2 entities) | 35 | $3,360 |
| Abbott | 39 | $1,394 |
| Novartis | 42 | $1,093 |
| Abiomed | 4 | $630 |
| E.r. Squibb & Sons, L.L.C. | 39 | $541 |
| Philips North America LLC | 26 | $452 |
| Boston Scientific | 13 | $407 |
| Johnson & Johnson(2 entities) | 19 | $372 |
| Boehringer Ingelheim | 8 | $296 |
| Pfizer | 14 | $226 |
| Biotronik Inc. | 5 | $145 |
| AstraZeneca | 9 | $132 |
| United Therapeutics Corporation | 1 | $125 |
| Novo Nordisk | 5 | $115 |
| Cvrx, Inc. | 2 | $114 |
| Sanofi-aventis U.S. LLC | 5 | $99 |
| Atricure, Inc. | 1 | $75 |
| Amgen | 4 | $73 |
| Actelion Pharmaceuticals US, Inc. | 2 | $56 |
| Elutia, Inc. | 3 | $54 |
| Baxter Healthcare | 1 | $50 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Merck | 2 | $28 |
| Edwards Lifesciences | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Hospira, Inc. | 1 | $16 |
| Terumo Medical Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$4,957
- Micra$742
- Impella$347
- AVEIR$313
- ASSURITY$230
- OMNIASECURE MRI SURESCAN$164
- Watchman$159
- COBALT DR MRI SURESCAN$141
- JARDIANCE$125
- XARELTO$119
- LEQVIO$118
- AZURE XT DR MRI SURESCAN$102
How this compares
$15,953 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 468 | $464,113 |
| XareltoRivaroxaban | 124 | $151,128 |
| Repatha SureclickEvolocumab | 35 | $42,668 |
| EntrestoSacubitril/Valsartan | 43 | $41,974 |
| Rosuvastatin Calcium | 591 | $8,695 |
| Atorvastatin Calcium | 579 | $6,190 |
| Metoprolol Succinate | 414 | $6,016 |
| Dofetilide | 39 | $5,283 |
| Flecainide Acetate | 81 | $3,542 |
| Ezetimibe | 121 | $2,256 |
| Ranolazine ErRanolazine | 14 | $2,244 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 182 | $1,451 |
| Potassium Chloride | 57 | $1,300 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 27 | $1,235 |
| Furosemide | 320 | $1,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $226 | $464,113468 claims |
| Johnson & JohnsonXarelto | $372 | $151,128124 claims |
| NovartisEntresto | $1,093 | $41,97443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Wilmington
- Carlos Arrieta GarciaWilmington$60K
- Linda CalhounWilmington$42K
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
- Adrian HernandezDurham$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.